James George Chopas Sells 783 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CAO James George Chopas sold 783 shares of the business’s stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $28.70, for a total transaction of $22,472.10. Following the transaction, the chief accounting officer now owns 37,358 shares of the company’s stock, valued at approximately $1,072,174.60. This represents a 2.05 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Apellis Pharmaceuticals Price Performance

NASDAQ APLS traded down $0.90 on Tuesday, hitting $27.69. 1,676,758 shares of the company’s stock were exchanged, compared to its average volume of 2,547,033. The stock has a 50-day moving average of $31.87 and a 200-day moving average of $33.55. The stock has a market cap of $3.44 billion, a price-to-earnings ratio of -13.64 and a beta of 0.94. Apellis Pharmaceuticals, Inc. has a 52 week low of $24.34 and a 52 week high of $71.90. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.14). The business had revenue of $196.83 million during the quarter, compared to analyst estimates of $200.00 million. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The business’s quarterly revenue was up 78.3% compared to the same quarter last year. During the same period last year, the business earned ($1.17) earnings per share. Analysts expect that Apellis Pharmaceuticals, Inc. will post -1.72 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Wolverine Asset Management LLC acquired a new position in Apellis Pharmaceuticals during the 3rd quarter worth about $27,000. True Wealth Design LLC bought a new stake in Apellis Pharmaceuticals in the third quarter valued at approximately $27,000. Capital Performance Advisors LLP acquired a new stake in Apellis Pharmaceuticals during the 3rd quarter valued at approximately $56,000. KBC Group NV lifted its position in shares of Apellis Pharmaceuticals by 34.8% in the 3rd quarter. KBC Group NV now owns 2,632 shares of the company’s stock worth $76,000 after purchasing an additional 679 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Apellis Pharmaceuticals by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company’s stock valued at $130,000 after purchasing an additional 781 shares during the last quarter. 96.29% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on APLS shares. Royal Bank of Canada reissued a “sector perform” rating and set a $25.00 price target on shares of Apellis Pharmaceuticals in a research report on Monday, November 4th. The Goldman Sachs Group cut Apellis Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $36.00 target price for the company. in a research note on Tuesday, December 17th. Evercore ISI raised Apellis Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, October 31st. Scotiabank cut their price objective on Apellis Pharmaceuticals from $35.00 to $30.00 and set a “sector perform” rating on the stock in a report on Wednesday, November 6th. Finally, Bank of America lowered their target price on Apellis Pharmaceuticals from $61.00 to $47.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. Eight research analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $46.65.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).